Skip to content

Search

New test proves effective in more cancers

Avantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited

National study to unravel triggers for childhood leukaemia

A national study is investigating diet, chemical exposure and genetic factors in a new bid to unravel the causes of childhood leukaemia.

WA families to help find triggers for childhood leukaemia

West Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.

Timo Lassmann

Feilman Fellow; Head, Precision Health Research and Head, Translational Intelligence

Setting the agenda: Urgent priorities to close the childhood cancer gap for Aboriginal and Torres Strait Islander children

A review led by the First Nations Childhood Cancer team at The Kids Research Institute Australia has highlighted the urgent need for Indigenous-specific studies focused on cancer outcomes, survivorship and equity.

New study uncovers dual benefit of bone-protecting treatment for childhood leukaemia

A groundbreaking study from cancer researchers at The Kids Research Institute Australia has identified a promising new therapeutic strategy for children battling the most common childhood cancer – B-cell acute lymphoblastic leukaemia.

A systematic review on the impact of delayed local therapy in patients with Ewing sarcoma of the pelvis

Local treatment of pelvic Ewing Sarcoma (EWS) is czhallenging due to complex anatomy and potential complications. Local therapy may be deferred to maintain chemotherapy dose-intensity, but the impact of this delay on outcomes remains unclear.

Pharmacological targeting and characterization of Voltage-Gated Sodium Channels (VGSCs) expressed in the high-grade glioma microenvironment

High-grade glioma (HGG) cells reactivate neurodevelopmental programs regulated by ion channels to drive tumor progression. The activity of voltage-gated sodium channels (VGSCs) is fundamental to development, a target of blood-brain barrier (BBB)-permeable FDA-approved drugs, and aids tumor advancement in several cancers. However, the contribution of VGSC activity to HGG pathology remains unknown.